Distribution agreement

About this update from Probiotix Health Plc

ProBiotix H eal th p l c ( "ProBiotix" or the "Company")   Distribution agreement Distribution of finished turnkey products in Australia and New Zealand   ProB i ot i x H ealth p l c (A QSE : PBX), a li f e sc i ences bu s i n ess d e ve l o p i n g probiotics to tack l e lifestyle conditions such as cardiovascular disease , announces that the Company has signed an exclusive distribution agreement with Trans Chem to cover the Australian and New Zealand probiotics market.   Trans Chem is one of Australia's leading independent suppliers of innovative products and quality raw ingredients for the pharmaceutical, nutraceutical, food and beverage,veterinary and animal nutrition industries. Trans Chem's operations extend across both Australia and New Zealand. Trans Chem's customers include all the major leading pharma and nutraceutical brand owners in the region and the numerous contract manufacturers who service and support these players. They also have a strong emerging international food and beverage business. The Directors believe that Trans Chem is a strong and creditable company, winning 'Prestigious Quality Material Supplier of the Year' awarded by the Complementary Medicines Australia (CMA) in 2016, 2019 and in 2021.   Steen Andersen, CEO of ProBiotix Health plc commented: "We are delighted to have signed this agreement with Trans Chem, which will further enhance our global reach. Although our primary strategic focus is on developing the European and North American markets, we believe that there is a significant business potential in Australia & New Zealand. Both countries have a high concentration of dietary supplement companies acting as a gateway into servicing mainland China and the Southeast Asian region, which we can now capitalise on.   "Trans Chem is a leading distributor in the region and will be responsible for selling our finished turn-key product solutions based on LP LDL ® into the leading brands in the regions. The finished turn-key product solutions will be manufactured through local Australian and New Zealand contract manufacturing organisations (CMO's), controlled by ProBiotix Health in cooperation with Trans Chem."       For further information, please contact:   ProBiotix Health plc https://probiotixhealth-ir.com/ Steen Andersen, Chief Executive Contact via Walbrook below Peterhouse Capital Ltd ( AQSE Corporate Adviser and Broker) Tel: 020 7469 0930 Mark Anwyl Duncan Vasey   Walbrook PR Ltd [email protected] Anna Dunphy Mob: 07876 741 001   Market Abuse Regulation (MAR) Disclosure This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).  

View stock analysis, news, and events for Probiotix Health Plc